Clearside Biomedical expands L –

ALPHARETTA, Ga., June 14, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (CLSD, Financial), a biopharmaceutical company revolutionizing the delivery of therapies to the fundus through the suprachoroidal space (SCS®), today announced the appointment of Susan L. Coultas, Ph.D., as Clinical Director. In this role, Dr. Coultas is a member of the leadership team and has overall responsibility for planning the initiation and execution of Clearside’s clinical trials, including overseeing all clinical development operations.

“We are thrilled to have Susan join our team,” said George Lasezkay, Pharm.D., JD, President and CEO of Clearside. “With her extensive clinical development experience at several leading ophthalmic companies, she will make a significant contribution to Clearside’s vision, strategy and operational efficiency. His expertise in advancing a therapy from the initial stages of clinical development to marketing approval will be a valuable asset as we continue to advance our lead candidate, CLS-AX (axitinib injectable suspension ) in patients with neovascular age-related macular degeneration (wet AMD). ). Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer, will continue his current responsibilities for clinical trial design and product portfolio strategy and development. Tom will work closely with Susan regarding the implementation and analysis of our clinical pipeline programs. »

“I am excited to join a dedicated team focused on developing a new generation of impactful treatments for retinal diseases using a proven approach with our suprachoroidal spatial injection platform,” said Susan L. Coultas , Ph.D., Clinical Director. “I look forward to working with the leadership team and supporting our clinical programs to realize the vast potential of our pipeline to benefit patients with sight-threatening eye diseases.”

Dr. Coultas brings 35 years of clinical development experience in the biopharmaceutical industry. Most recently, she served as Senior Vice President of Clinical Development at Kala Pharmaceuticals, where she was responsible for the planning and execution of its clinical programs, which resulted in two new drug application filings and product approval. Dr. Coultas has worked with several ophthalmology companies, both in-house and as a consultant, including Alcon Laboratories, Inc., CibaVision Ophthalmics, Sucampo Pharmaceuticals, and Bausch + Lomb, Inc. Earlier in his career, as As owner of InfoQuest Clinical Network, Inc., Dr. Coultas has successfully identified, developed and led an extensive network of clinical research professionals who have managed numerous clinical trials in multiple systemic and ophthalmic therapeutic areas. Dr. Coultas earned a Ph.D. in public health, epidemiology, from Walden University, a master’s degree in biology from the University of North Texas, and a bachelor’s degree in biology from Texas Wesleyan University.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the company’s proprietary SCS microinjector®, enables an in-office, reproducible, and non-surgical procedure for the targeted, compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with diseases eyesight threatening. Clearside is developing its own pipeline of small molecule product candidates to be delivered through its SCS microinjector and strategically partners its SCS injection platform with companies using other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the United States. For more information, please visit

Caution Regarding Forward-Looking Statements

Any statements in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “believe ‘, ‘expect’, ‘may’, ‘plans’, ‘potential’, ‘will’ and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of Clearside’s product candidates, including CLS-AX. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in these statements. Risks and uncertainties that could cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s dependence on third parties over which it does not always have full control, uncertainties regarding the pandemic of COVID-19 and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the United States Securities and Exchange Commission (SEC) on March 11, 2022, and in Clearside’s other periodic reports filed with the SEC. All forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this press release, and Clearside assumes no obligation and does not intend to updates forward-looking statements. , whether as a result of new information, future events or otherwise.

Investor and media contacts:

Jenny Kobin
Remy Bernarda
[email protected]
(678) 430-8206

Source: Clearside Biomedical, Inc.


Comments are closed.